Weight changes and adverse pregnancy outcomes with dolutegravir- and tenofovir alafenamide fumarate-containing antiretroviral treatment regimens during pregnancy and postpartum.
Hoffman RM, Brummel S, Ziemba L, Chinula L, McCarthy K, Fairlie L, Jean-Philippe P, Chakhtoura N, Johnston B, Krotje C, Nematadzira TG, Nakayiwa F, Ndyanabangi V, Hanley S, Theron G, Violari A, João E, Correa Junior MD, Hofer CB, Navanukroh O, Aurpibul L, Nevrekar N, Zash R, Shapiro R, Stringer JSA, Currier JS, Sax P, Lockman S; IMPAACT 2010/VESTED Study Team.
Hoffman RM, et al. Among authors: chinula l.
Clin Infect Dis. 2024 Jan 5:ciae001. doi: 10.1093/cid/ciae001. Online ahead of print.
Clin Infect Dis. 2024.
PMID: 38180851